L’ivermectine (Stromectol) est un antiparasitaire dont l’action repose sur la liaison sélective aux canaux chlore activés par le glutamate présents dans les cellules nerveuses et musculaires des parasites. Cette fixation entraîne une augmentation du flux de chlore, provoquant une hyperpolarisation et une paralysie irréversible. L’ivermectine est active contre la gale, l’onchocercose et certaines strongyloïdoses. Sa biodisponibilité orale est variable, augmentée par la prise alimentaire, et son élimination est principalement fécale via un métabolisme hépatique. Elle ne traverse pas la barrière hémato-encéphalique, ce qui limite les effets neurologiques chez l’homme. Les précautions concernent l’interaction avec les inhibiteurs du CYP3A4, ainsi que les réactions inflammatoires dues à la destruction massive des parasites. Dans les documents de référence, stromectol prix est associé à des protocoles précis adaptés aux différentes infestations, avec une attention particulière sur la sécurité d’emploi en cas d’immunodépression.

Viii-4_escolhas_03.qxd

Escolhas do Director / Editor's Choices Glaucoma induzido pelo
topiramato
alterações da fala, a disfunção cogni- pressão intra-ocular (Fra u n felder e t Topiramate-Induced
Glaucoma
perda de visão (Fraunfelder et al., pelo topiramato (Sankar et al., 2001), t o p i ra m a t o, outros efeitos laterais de mente norm a i s. Isto é part i c u l a r- tratamento da perturbação de stress coroideias (Fra u n felder e t a l., 2004).
nas (Zullino et, 2002; Cheseaux et a l., 2003), cleptomania (Dannon, mato (Hulihan, 2006), fo ram descri t o s et al., 2002), agressão (Nickel et al., d e s c ritos em mulheres (Thambi e t a l., (Fong et al., 2005), promoção da 36 anos (Fra u n felder e t a l., 2004), cura de feridas (Shapira et al., 2003) Escolhas do Director / Editor's Choices Markind JE. (1998). Topiramate: a new antiepi- (2004). Topiramate-associated acute, bilateral, leptic drug. Am J Health Syst Pharm.; 55(6): Ophthalmology.; 111(1): 109-111.
Berlant J. (2001). Topiramate in chronic civilian Hulihan J. (2006). Important drug warning.
2 0 0 4 ). R a ramente são refe ri d a s post-traumatic stress disorder: an open-label study of a novel treatment. Presented at: 41st Evaluation Unit; May 28-31; Phoenix, Arizona.
Thambi L, Kapcala LP, Chambers W, et al. Weber MV. (2002). Topiramate for obstructive angle-closure glaucoma: a case series. Arch sleep apnea and snoring. Am J Psychiatry.
Zullino DF, Cottier AC, Besson J. (2002).
Topiramate in opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 26(6): Cheseaux M, Monnat M, Zullino DF. (2003).
Convulsões associadas
Topiramate in benzodiazepine withdrawal. Hum ao aripiprazol
Psychopharmacol.; 18(5): 375-377.
Dannon PN. (2003). Topiramate for the treat- Aripiprazole-Associated
ment of kleptomania: a case series and review of the literature. Clin Neuropharmacol.; 26(1): Komanduri R. Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry.; 64 Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK. (2002). Topiramate attenua- tes self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol. ; 5(2): Nickel MK, Nickel C, Kaplan P, et al. (2005).
Treatment of aggression with topiramate in male borderline patients: a double-blind, pla- cebo-controlled study. Biol Psychiatry.; 57(5): Fong TW, De La Garza R, Newton TF. (2005).
A case report of topiramate in the treatment of nonparaphilic sexual addiction. J Clin Psychopharmacol.; 25(5): 512-514.
Shapira NA, Lessig M, Murphy TK, Annis AM, Lazoritz M. (2003). Evaluation of open-label topiramate for scar therapy. Dermatol Online J.; Johnson J, Bourgeois JA, Quanbeck C. (2006).
Treatment of olfactory hallucinations with topi- ramate [letter]. J Clin Psychopharmacol.; 26(3): S wainston Harrison T, Pe r ry CM. ( 2 0 0 4 ).
Shorvon SD. (1996). Safety of topiramate: A ri p i p ra zo l e : a rev i ew of its use in schizo p h- adverse events and relationships to dosing.
renia and schizo a f fe c t i ve disorder. D ru g s.
Epilepsia.; 37 (suppl 2): S18-S22.
2 0 0 4 ; 6 4 ( 1 5 ) : 1 7 1 5 - 1 7 3 6.
Sankar PS, Pasquale LR, Grosskreutz CL.
Tsai J-F. ( 2 0 0 6 ). A ri p i p ra zole-associated sei- (2001). Uveal effusion and secondary angle- zure (letter). J Clin Psychiatry.
closure glaucoma associated with topiramate 2 0 0 6 ; 6 7 ( 6 ) : 9 9 5 - 9 9 6.
use. Arch Ophthalmol. ; 119(8): 1210-1211.
Klufas A, Thompson D. (2001). Topiramate- induced depression. Am J Psychiatry.; 158 Fraunfelder FW, Fraunfelder FT, Keates EU.
Escolhas do Director / Editor's Choices cações. Entre o 13º e o 15º dias apa- Co-adminstração de
paroxetina e intoxicação
lar fibrilação auri c u l a r, tendo sido digitálica
Pa roxetine Coadministration
Results in Digitalis
I n t ox i c a t i o n
objecto de vigilância clínica apert a d a.
depressão m a j o r. A sua históri a lação auricular, tratada nos últimos 2 Yasui-Furukori N, Kaneko S. (2006). Digitalis intoxication induced by paroxetine co-adminis- tration. Lancet. 2006;367(9512):788.
sentar náuseas, vómitos e tonturas.
ções visuais e desorientação. Ao 10º

Source: http://www.saude-mental.org/pdf/vol8_rev4_escolhas_director.pdf